Nonvenereal Syphilis Treatment Market Trends

  • Report ID: 3569
  • Published Date: Nov 19, 2025
  • Report Format: PDF, PPT

Nonvenereal Syphilis Treatment Market - Growth Drivers and Challenges

Growth Drivers

  • Rising Prevalence of Infectious Diseases – diseases such as syphilis, bejel, pinta, and yaws are rare but it’s increasing prevalence worldwide is leading to surging investments in its prevention & treatment which is expected to boost the growth of the nonvenereal syphilis treatment market in the projected years. Centers for Disease Control and Prevention unveiled that in 2019 around 129,813 cases of all stages of syphilis, were reported worldwide.

  • Growing Burden of Incidences Associated with Bacterial Pathogens – as per a study nearly 7·7 million deaths globally were associated with 33 different bacterial pathogens (both resistant and susceptible to antimicrobials), which comprised nearly 13·6% of all global deaths and 56·2% of all sepsis-related deaths in 2019. Owing to these widespread concerns about bacterial pathogens, the government of various countries is joining hands to eradicate diseases caused by different pathogens, which will indirectly result in improved rapid diagnostic tests to detect syphilis and nonvenereal syphilis and its treatment.

  • Rising Cases of Diseases Caused by Treponema species – diseases such as yaws are gaining prevalence, mostly in children. It is observed that nearly 75–80% of people affected by yaws are children under 15 years of age with peak incidences occurring in children aged 6–10 years. Hence, this has elevated research on medications and treatment of diseases caused by Treponema species that also cause bejel, and pinta and is morphologically and serologically indistinguishable from the agent syphilis This, as a result, is expected to propel the market growth in the projected years.

  • Strategies to Eradicate Neglected Tropical Diseases – World Health Organization (WHO) has drawn a 2021-2030 roadmap for the eradication of rare tropical diseases which include syphilis, yaws, and bejel to attain the Sustainable Development Goals. The roadmap was prepared through an extensive global consultation pursuant to decision EB146(9) of the Executive Board at WHO’s 146th session in February 2020.

Challenges

  • Persistent Challenges in the Diagnostic Landscape and Testing Models – are hindering global nonvenereal syphilis control efforts. The challenges in the diagnosis of active syphilis infection, bejel, yaws, and pinta diseases owing to insufficient research and development in key areas and the present technological, individual, and structural barriers in access to nonvenereal syphilis testing is a major restraining factor of nonvenereal syphilis treatment market.

  • Lack of Highly Trained Laboratory Technologists and Complex/ Expensive Laboratory Instruments

  • Lack of Healthcare Infrastructure


Base Year

2025

Forecast Year

2026-2035

CAGR

8.9%

Base Year Market Size (2025)

USD 381.03 million

Forecast Year Market Size (2035)

USD 893.8 million

Regional Scope

  • North America (U.S., and Canada)
  • Asia Pacific (Japan, China, India, Indonesia, Malaysia, Australia, South Korea, Rest of Asia Pacific)
  • Europe (UK, Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Latin America (Mexico, Argentina, Brazil, Rest of Latin America)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)

Browse key industry insights with market data tables & charts from the report:

Frequently Asked Questions (FAQ)

In the year 2026, the industry size of nonvenereal syphilis treatment is assessed at USD 411.55 million.

The global nonvenereal syphilis treatment market size was valued at around USD 381.03 million in 2025 and is projected to grow at a CAGR of more than 8.9%, reaching USD 893.8 million revenue by 2035.

By 2035, the Middle East & Africa region is poised to command the leading share in the Nonvenereal Syphilis Treatment Market, spurred by the persistent presence of nonvenereal syphilis across West Africa, the Mediterranean, and the Sahara owing to poor sanitization and hot, humid climatic conditions.

Key players in the market include Pfizer, Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Novartis International AG, Sanofi S.A., GlaxoSmithKline plc, Merck & Co., Inc., Otsuka Pharmaceutical Co., Ltd., Abbott Laboratories, Cipla Limited.
Inquiry Before Buying Request Free Sample PDF
footer-bottom-logos